Libra Infusions Ltd (LBRA)

Currency in BDT
776.20
-0.90(-0.12%)
Closed·

LBRA Financial Summary

Key Ratios

P/E Ratio1,309.36
Price/Book1.05
Debt / Equity46.44%
Return on Equity0.08%
Dividend Yield0.00%
EBITDA28.79M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2010
31/12
2011
30/06
2012
30/06
2013
30/06
2014
30/06
2015
30/06
2016
30/06
2017
30/06
2018
30/06
2019
30/06
* In Millions of BDT (except for per share items)

Earnings

Latest Release
Jul 02, 2019
EPS / Forecast
-7.59 / --
Revenue / Forecast
35.15M / --
EPS Revisions
Last 90 days

FAQ

What were Libra Infusions's earnings for the latest quarter?

The Libra Infusions EPS (TTM) is 0.70. Libra Infusions reported sales of 35.15, net income of -17.10, and EPS of -7.59 for the latest quarter.

What was Libra Infusions's net income for the latest quarter?

Libra Infusions's net income for the latest quarter was -17.10.

How did Libra Infusions's performance compare year-over-year in the latest quarter?

The company's revenue moved from 51.75 in the previous quarter to 35.15 in the latest quarter, and net income moved from -12.25 to -17.10 compared to the previous quarter.

What is Libra Infusions's net profit margin on a TTM basis?

Libra Infusions's trailing twelve months (TTM) net profit margin is 0.80%.

How does Libra Infusions's debt to equity ratio compare to industry standards?

Libra Infusions's total debt-to-equity ratio is 46.44%.

What is Libra Infusions's return on investment on a TTM basis?

Libra Infusions's trailing twelve months (TTM) return on investment (ROI) is 0.08%.

Did Libra Infusions gain or lose cash last quarter?

In the latest quarter, Libra Infusions's net change in cash was -7.27 million.

What were Libra Infusions's total assets and liabilities in the latest quarter?

As of the latest quarter, Libra Infusions reported total assets of 4,588.88 million and total liabilities of 1,880.93 million.

How has Libra Infusions's total revenue grown this year?

Libra Infusions's total revenue was 51.75 in the previous quarter and 35.15 in the latest quarter.

What was Libra Infusions's revenue per share for the latest quarter?

Libra Infusions's revenue per share for the latest quarter was 132.76.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.